Multiple sclerosis: closing in on an oral treatment.
Martin
Roland
R
D000284:Administration, Oral; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D017326:Clinical Trials, Phase III as Topic; D000068876:Fingolimod Hydrochloride; D006801:Humans; D008246:Lysophospholipids / Q000378:metabolism; D008942:Mitoxantrone / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D000069442:Natalizumab; D011409:Propylene Glycols / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013110:Sphingosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D008246:Lysophospholipids; D000069442:Natalizumab; D011409:Propylene Glycols; C060506:sphingosine 1-phosphate; D008942:Mitoxantrone; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine